| |
|
|
|
Table of Contents
|
Chapter 3 - Multiple Sclerosis Treatments In Development
|
Improved understanding of MS pathophysiology has led to identification of new targets and development of numerous new therapies. In Chapter 3 of Living Medical Textbook: Multiple Sclerosis Edition, Dr. Clyde Markowitz reports on a number of emerging MS therapies in development, focusing on study data, mechanism of action, and side effects of each agent.
 top
|
|
Chapter 2 - Standard-of-Care Treatment of Multiple Sclerosis
|
This second chapter in the Living Medical Textbook on multiple sclerosis (MS) reviews the current standard of care for acute and chronic treatment. Dr. Cohen provides an up-to-date account of available therapies for treating acute relapse and use of disease-modifying therapies to prevent relapse and disease progression. He describes the mechanism of action, efficacy, safety, dosing, and administration of each therapy. Comparative data are considered, along with individualized patient factors that should influence choice of initial therapy. Dr. Cohen also discusses candidacy for treatment and timing of therapy, including the latest data on the merits of initiating therapy in patients with clinically isolated syndrome. Hyperlinks throughout the chapter extend learning by providing greater depth on selected key topics.
 top
|
|
Chapter 1 - Multiple Sclerosis Basics
|
Multiple Sclerosis Basics is the first chapter of a Living Medical Textbook on the comprehensive management of multiple sclerosis (MS). In this chapter, Scott Zamvil, MD, provides a broad overview of current thinking and controversies regarding the etiology, pathogenesis, classification, and diagnosis of MS. Hyperlinks throughout the chapter lead the reader to more detailed and specific information on these topics from a variety of sources on the Internet in a multitude of formats. The discussion of immunopathogenesis and disease course of MS in Chapter 1 sets the stage for the next two chapters of this book, which will focus on current and emerging MS therapies, including their mechanisms of action, efficacy, and safety.
 top
|
|
| |
| |
|
|
CME INFORMATION
|
ACTIVITY GOAL |
| The goal of this CME/CE activity is to examine the pathophysiology, etiologic factors, classification, diagnostic criteria, and current and emerging strategies for treating and managing patients with multiple sclerosis. |
| |
TARGET AUDIENCE |
| This CME/CE activity is designed for neurologists, internal medicine specialists, family practice/primary care physicians, nurse specialists/nurse practitioners, physician assistants, and other health professionals who interact with and are involved in the management and treatment of patients with multiple sclerosis. |
| |
LEARNING OBJECTIVES |
- Analyze the contributions of proposed etiologies and pathogenetic processes in MS based on current data in order to appropriately counsel patients and form the basis of an understanding of potential therapeutic targets.
- Diagnose and classify MS in patients with neurologic symptoms, using clinical, radiologic, and other tools, in accordance with the modified McDonald Criteria.
|
| top1876 |
|
|
|
|
These independent CME/CE activities are supported by an educational grant from Teva Neuroscience.
|
|
Professor
Davee Department of
Neurology
Feinberg School of
Medicine
Northwestern University
Chicago, Illinois
|
|
|
|
|
Director, Multiple
Sclerosis Center
University of Pennsylvania
Philadelphia, Pennsylvania
|
|
|
|
|
Associate Professor
Department of Neurology
Program in Immunology
University of California,
San Francisco
San Francisco, California
|
|
|
|
|